Skip to content
2000
Volume 23, Issue 3
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

Diabetes mellitus has been associated with a higher risk of exocrine pancreas disorders despite inconsistencies among studies, presumably due to the presence of several (often unmeasured) confounding factors. As a direct consequence of this uncertainty, the relationship between anti-diabetic therapies and pancreatic adverse reactions is difficult to evaluate and remains far from being clarified. Indeed, the on going debate on the safety of incretin-based therapies does not lie in any definite conclusion. Serum level of amylases and lipase reflects the balance between production from different tissues and clearance, but it may be also influenced by numerous molecular, cellular, and systems mechanisms. The present review tries to provide an overview of potential biochemical pathways that may underlie pancreatic hyperenzymemia in health and diabetes mellitus.

Loading

Article metrics loading...

/content/journals/cmc/10.2174/0929867323666151207111201
2016-01-01
2025-09-02
Loading full text...

Full text loading...

/content/journals/cmc/10.2174/0929867323666151207111201
Loading

  • Article Type:
    Research Article
Keyword(s): adverse drug reaction; amylases; Diabetes mellitus; lipase; pancreatitis
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test